TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05913752: A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

Sponsor: Clearmind Medicine Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 84 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,132,420

Rescue Site Savings

+$2,060,060

Unlock Full NCT05913752 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05913752 Rescue Dossier →